Print Magazine
Brussels Morning Newspaper
Sunday, January 29, 2023
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
No Result
View All Result
Home Europe

Irish company to infect young people with COVID-19 in new trials

Sophia Akram by Sophia Akram
24 September 2020
in Europe, Features
Irish company to infect young people with COVID-19 in new trials
Share on FacebookShare on Twitter

A medical lab with Irish owners will be conducting unprecedented Covid-19 challenge trials using human volunteers.

Dublin-based Open Orphan acquired trial leaders hVivo this year.

The laboratory that has links with Imperial College and Queen Mary’s University is using a London-based quarantine site to test vaccines by inoculating young people and then giving them a “challenge” dose of Sars-Cov-2, which causes Covid-19.

Researchers told the Financial Times the trials should “narrow the large field of promising Covid-19 vaccines” that will be tested next year.

Challenge trials will reportedly commence in January.

Around 2,000 people have signed up as volunteers through campaign group 1Day sooner to help enlist the vast numbers of tests needed for a viable clinical trial.

Lead organiser of the campaign, 18-year-old Alastair Fraser-Urquhart, said, “By exposing just a few hundred carefully selected young, healthy people to coronavirus…we can test a huge range of vaccines very quickly”.

The trials will involve adopting a strain of the coronavirus that genetically represents Sars-CoV-2 that’s being spread among the population and selecting doses that won’t overburden volunteers’ immune system.

A “rescue remedy” will be on hand to prevent the occurrence of serious illness. Remedsevir will be used as the only drug that has worked against Covid-19.

Volunteers in the challenge will be compensated with up to £3,750 (around €4,100).

hVivo will use the 24-bed facility in the east end of London in the first instance but will look at other facilities as it tests further vaccines.

The trials must get approval from both an independent research ethics committee and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

“The safety of trial participants is our top priority”, said MHRA, speaking to the Financial Times. It stressed that any proposal for human infection challenge as part of a vaccine trial “would be considered on a benefit-risk basis, with risks monitored for and minimised in the proposed trial design”.

Tags: Covid-19Vaccination
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Belgium News
  • Brussels
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • Health & Fitness
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • About Us
  • Brussels Bubble
    • Parliament
    • Commission
    • Council
  • Wider Europe
    • Member States
  • World
  • Business & Society
  • Europe With Transparency
  • Culture & Society
  • Policy Talks
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • Ambassador’s Corner
    • The American Angle
    • Southeast Europe
  • Print Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT